URALYT®-U


Granules 280 g
scheduling status
S0
registration number
H/18.4/1773
What URALYT®-U is and what it is used for
1. To dissolve uric acid calculi in the urinary tract and to prevent further stone formation. 2. To alkalinise the urine during treatment with uricosuric agents and during cytostatic therapy.
dosage
The treatment is divided into two stages: 1. Initial adjustment of the dose of Uralyt®-U to a level which brings the pH of the urine into the desired range. 2. Long term administration of Uralyt®-U, with regular checks by the patient. The granules should be dissolved by stirring in half a glass of water or fruit juice and taken, preferably, after meals. Unused solution must be discarded. The dosage of Uralyt®-U is adjusted in accordance with the pH value of the urine. This is done as follows: 1. Measure the pH of the urine with the indicator paper. 2. Enter the pH value (colour number) on the enclosed test chart. 3. Take the corresponding dose (number of measuring spoonfuls of Uralyt®-U) and enter it on the chart. Check the pH value of the urine before each dose of Uralyt®-U. This pH value (5,6; 5,9; 6,2;6,5; 6,8; 7,0; 7,2; 7,4; 7,7; 8,0) shows the response from the previous dose of Uralyt®-U. The morning test shows the response from the previous evening dose, the midday test shows the response from the morning dose, etc.
how to take
The enclosed measuring spoon holds approximately 2,5 g of the granules. For most patients it has proved satisfactory to take an average daily dose of 4 measures of the granules (10 g Uralyt®-U) spread uniformly throughout the day in accordance with the following schedule: Time | Number of spoonfuls MORNING as early as possible (7-8 a.m.) | 1 MIDDAY 2-3 p.m | 1 EVENING as late as possible (about 10 p.m.) | 2 This is the standard dosage to stabilise the urine pH within the desired range (6,2 to 6,8) and is the range required for treatment of Uric Acid Calculi.
What URALYT®-U contains
Potassium sodium hydrogen citrate.
other ingredients
Oil of lemon; purified water; Sunset Yellow FCF E110 C.I. No. 15985.
Therapeutic classification
G04BC01.
© 2026 SAHPRA. ALL RIGHTS RESERVED